Deutsche Bank AG Buys 904,613 Shares of Bristol-Myers Squibb (NYSE:BMY)

Deutsche Bank AG lifted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 10.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,566,461 shares of the biopharmaceutical company's stock after buying an additional 904,613 shares during the period. Deutsche Bank AG owned 0.47% of Bristol-Myers Squibb worth $541,079,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in Bristol-Myers Squibb by 701.2% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock valued at $705,309,000 after acquiring an additional 10,913,708 shares during the period. EP Wealth Advisors LLC boosted its position in Bristol-Myers Squibb by 4.7% during the 4th quarter. EP Wealth Advisors LLC now owns 51,589 shares of the biopharmaceutical company's stock valued at $2,918,000 after purchasing an additional 2,337 shares during the period. CoreCap Advisors LLC grew its stake in Bristol-Myers Squibb by 23.6% during the 4th quarter. CoreCap Advisors LLC now owns 17,501 shares of the biopharmaceutical company's stock worth $990,000 after buying an additional 3,345 shares during the last quarter. Cornerstone Select Advisors LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter worth $1,618,000. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in Bristol-Myers Squibb by 36.4% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 513,727 shares of the biopharmaceutical company's stock valued at $29,056,000 after buying an additional 137,203 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BMY. Jefferies Financial Group dropped their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Citigroup lifted their price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a report on Friday, February 7th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Finally, Piper Sandler initiated coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Trading Down 1.1 %

BMY traded down $0.50 during trading on Friday, reaching $46.38. The company had a trading volume of 14,913,246 shares, compared to its average volume of 13,105,378. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The company has a market cap of $94.39 billion, a price-to-earnings ratio of -10.49, a PEG ratio of 2.07 and a beta of 0.39. The firm's 50-day simple moving average is $54.54 and its 200 day simple moving average is $56.21.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same quarter in the prior year, the company earned ($4.40) earnings per share. The company's revenue for the quarter was down 5.6% on a year-over-year basis. Equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.35%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 4,250 shares of the stock in a transaction on Friday, April 25th. The shares were purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president now directly owns 83,513 shares of the company's stock, valued at $3,973,548.54. This trade represents a 5.36 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.09% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.